GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

GSK is a Brentford, UK-based pharmaceutical company.

Results from the DREAMM-8 phase three trial evaluating Blenrep, in combination with pomalidomide plus dexamethasone, versus a standard of care bortezomib plus PomDex, met its primary endpoint of progression-free survival, the firm said.

As part of the trial, a total of 302 participants received either belantamab mafodotin plus PomDex, or bortezomib plus PomDex, where "consistent efficacy" was observed.

Last month, GSK had reported positive trial data for Blenrep in its DREAMM-7 phase three trial, which showed a 59% reduction in risk of disease progression or death observed in patients with Blenrep combination versus standard of care daratumumab combination.

In December, Europe's health regulator, the European Medicines Agency, stuck to its recommendation not to renew conditional approval for Blenrep, citing data that did not confirm its effectiveness.

MM is a form of blood cancer. According to GSK, there are approximately 176,000 new cases of MM diagnosed globally each year.

Senior Vice President, Global Head Oncology, Research & Development at GSK, Hesham Abdullah, said: "The results seen in both DREAMM-7 and DREAMM-8 provide strong clinical evidence of the robust efficacy shown with belantamab mafodotin in use with standard of care combinations. We now look forward to discussing these data with regulators. If approved, we believe these combinations have the potential to redefine the treatment of relapsed or refractory multiple myeloma and advance the standard of care. This is exciting news for patients, given the high unmet medical need for both efficacious and easily administered therapies with differing mechanisms of action."

Shares in GSK were up 1.9% at 1,705.00 pence each in London on Thursday morning.

By Sabrina Penty, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.